News | March 25, 2009

Lantheus to Present New Cardiac Imaging Data at ACC

March 25, 2009 – Lantheus Medical Imaging Inc. today announced that new data for the company’s echocardiography contrast agent DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension and its novel fluorine 18-labeled Positron Emission Tomography (PET) agent for myocardial perfusion imaging, BMS747158, will be presented in two separate poster presentations at the American College of Cardiology 58th Annual Scientific Session on March 29-31, 2009, in Orlando, Florida.

New data on survival in an intensive care unit population undergoing transthoracic echocardiography with and without perflutren containing ultrasound contrast agents will be presented. The retrospective study includes more than 39,000 propensity-matched cases in patients undergoing transthoracic echocardiography with and without contrast agents. The majority of the perflutren cases used DEFINITY, which is the market-leading product in ultrasound echocardiography contrast agents in the U.S. Additionally, Phase I data regarding the human safety, dosimetry, biodistribution, and myocardial perfusion imaging characteristics under rest and stress conditions of Lantheus’ new PET agent BMS747158 will be presented.

“The new DEFINITY data expand on findings published in December 2008 that showed that the use of DEFINITY for enhancing suboptimal resting echocardiography exams was associated with a 26 percent lower risk of mortality when compared with echocardiography performed without a contrast agent. Additionally, the PET agent data further demonstrate Lantheus’ ongoing commitment to developing new agents for the diagnosis and management of cardiovascular disease,” said Don Kiepert, president and CEO, Lantheus Medical Imaging, Inc.

The abstract “Survival in an Intensive Care Unit Population Undergoing Transthoracic Echocardiography With and Without Perflutren Containing Ultrasound Contrast Agents: Results in 39,189 Propensity Matched Cases” will be presented on Sunday, March 29, 2009, 3:30 p.m. - 4:30 p.m. The presenter is Michael L. Main M.D., associate professor of medicine, University of Missouri-Kansas City and director, echocardiography laboratory, Saint Luke’s Mid America Heart Institute, Kansas City, MI.

The second abstract, “Phase 1 Human Safety, Dosimetry, Biodistribution, and Rest/Stress Myocardial Imaging Characteristics of F-18 Labeled BMS747158,” will be presented on Tuesday, March 31, 2009, 9:30 a.m. - 10:30 a.m., by Jamshid Maddahi, M.D., F.A.C.C., professor of molecular and medical pharmacology (nuclear medicine) and medicine (cardiology) at David Geffen School of Medicine at UCLA.

For more information: www.lantheus.com

Related Content

ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.
Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...